T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use
09 Junho 2023 - 10:15AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens and antibiotic resistance
genes, today announced a collaborative relationship with Vanderbilt
University Medical Center’s (VUMC) Learning Healthcare System (LHS)
Platform, which unites clinical research and clinical operations to
evaluate and implement new approaches to care that can improve the
health of patients and the community. Through this collaboration,
VUMC will implement and evaluate the FDA-cleared T2Bacteria® Panel
in a clinical setting and conduct a prospective study to assess the
impact of the direct-from-blood T2Bacteria Panel to improve
antibiotic usage and clinical interventions for patients with a
bloodstream infection.
"Vanderbilt University Medical Center is one of
the leading healthcare institutions in the country and we are
excited to partner with them to bring our life-saving sepsis
pathogen detection products to their patients and providers,”
stated John Sperzel, Chairman and CEO of T2 Biosystems. “The
Vanderbilt Learning Healthcare System Platform provides a unique
opportunity to show the benefit of rapid, culture-independent
diagnostics and further demonstrate the value of the T2Bacteria
Panel in rapidly identifying causative bacterial pathogens in
septic patients.”
About T2Bacteria Panel The
T2Bacteria Panel is the only FDA-cleared diagnostic test able
to detect sepsis-causing bacterial pathogens directly from whole
blood, in 3 to 5 hours, without the need to wait days for a
positive blood culture. The T2Bacteria Panel runs on the
fully-automated T2Dx Instrument and simultaneously detects five
bacteria species, including E. faecium, S. aureus, K.
pneumoniae, P. aeruginosa, and E. coli, and the CE marked
version detects the aforementioned pathogens plus A. baumannii.
Rapid detection of these pathogens is essential to getting infected
patients on appropriate antibiotic therapy and improving clinical
outcomes.
About T2 BiosystemsT2
Biosystems, a leader in the rapid detection of sepsis-causing
pathogens and antibiotic resistance genes, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, the T2Bacteria®
Panel, the T2Candida® Panel, the T2Resistance® Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Biothreat™ Panel, the T2Cauris™
Panel, and T2Lyme™ Panel, as well as next-generation products for
the detection of bacterial and fungal pathogens and associated
antimicrobial resistance markers. For more information, please
visit www.t2biosystems.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including, without limitation, statements regarding the
potential benefit of rapid, culture-independent diagnostics and the
ability to demonstrate the value of the T2Bacteria Panel in rapidly
identifying causative bacterial pathogens in septic patients, as
well as statements that include the words “expect,” “may,”
“should,” “anticipate,” and similar statements of a future or
forward-looking nature. These forward-looking statements are based
on management’s current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, (i) any inability to (a) realize anticipated benefits
from commitments, contracts or products; (b) successfully execute
strategic priorities; (c) bring products to market; (d) expand
product usage or adoption; (e) obtain customer testimonials; (f)
accurately predict growth assumptions; (g) realize anticipated
revenues; (h) incur expected levels of operating expenses; or (i)
increase the number of high-risk patients at customer facilities;
(ii) failure of early data to predict eventual outcomes; (iii)
failure to make or obtain anticipated FDA filings or clearances
within expected time frames or at all; or (iv) the factors
discussed under Item 1A. “Risk Factors” in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2022, filed
with the U.S. Securities and Exchange Commission, or SEC, on March
31, 2023, and other filings the Company makes with the SEC from
time to time, including our Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. These and other important factors
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s
estimates as of the date of this press release. While the Company
may elect to update such forward-looking statements at some point
in the future, unless required by law, it disclaims any obligation
to do so, even if subsequent events cause its views to change.
Thus, no one should assume that the Company’s silence over time
means that actual events are bearing out as expressed or implied in
such forward-looking statements. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this press release.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupir@T2Biosystems.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024